Multiple Sclerosis Risk Relapse After Natalizumab Discontinuation During Pregnancy

Two studies published in the Neurology evaluated the maternal and fetal consequences of stopping the monoclonal antibody natalizumab in women with multiple sclerosis either well before pregnancy or within the first few days of the pregnancy. The studies evaluated 92 pregnancies.

Related Links